Associated Genetic Biomarkers
ANO1 status serves as an inclusion eligibility criteria in 5 clinical trials, of which 5 are open and 0 are closed. Of the trials that contain ANO1 status as an inclusion criterion, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open).
Trials with ANO1 status in the inclusion eligibility criteria most commonly target gastrointestinal stromal tumor .
The most frequent alteration to serve as an inclusion eligibility criterion is ANO1 Expression .
Imatinib, observation, paclitaxel, regorafenib, and spartalizumab are the most frequent therapies in trials with ANO1 as an inclusion criteria .
Significance of ANO1 in Diseases
Gastrointestinal Stromal Tumor +
ANO1 is an inclusion criterion in 5 clinical trials for gastrointestinal stromal tumor, of which 5 are open and 0 are closed. Of the trials that contain ANO1 status and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open), 3 are phase 2 (3 open), and 1 is phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.